The Korean journal of internal medicine

  • 제33권1호
  • /
  • Pages.168-175
  • /
  • 2018
  • /
  • 1226-3303(pISSN)
  • /
  • 2005-6648(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer

  • Baek, Min Young (Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center) ;
  • Ahn, Hee Kyung (Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center) ;
  • Park, Kyu Ree (Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center) ;
  • Park, Hwa-Sun (Department of Internal Medicine, Gachon University Gil Medical Center) ;
  • Kang, Shin Myung (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Gachon University Gil Medical Center) ;
  • Park, Inkeun (Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center) ;
  • Kim, Young Saing (Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center) ;
  • Hong, Junshik (Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center) ;
  • Sym, Sun Jin (Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center) ;
  • Park, Jinny (Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center) ;
  • Lee, Jae Hoon (Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center) ;
  • Shin, Dong Bok (Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center) ;
  • Cho, Eun Kyung (Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center)
  • 투고 : 2015.06.06
  • 심사 : 2015.10.19
  • 발행 : 2018.01.01
⟨ 이전 논문 다음 논문 ⟩

초록

Background/Aims: We investigated the time taken for patients with metastatic non-small cell lung cancer (NSCLC) to develop brain metastases (BM), as well as their subsequent overall median survival following diagnosis, considering the epidermal growth factor receptor (EGFR) mutational status. Methods: We retrospectively investigated the medical records of 259 patients diagnosed with advanced NSCLC from January 2010 to August 2013, who were tested for EGFR mutations. The time from the diagnosis of advanced NSCLC to the development of BM and the overall median survival after BM development (BM-OS) were evaluated and compared by EGFR mutational status. Results: Sixty-seven patients (25.9%) developed BM. Synchronous BM occurred more often in patients with EGFR mutation type (MT) (n = 20, 27.4%) compared with EGFR wild type (WT) (n = 27, 14.5%, p < 0.009). The median BM-OS was significantly longer in patients with EGFR MT than in those with EGFR WT (25.7 months vs. 3.8 months, p < 0.001), and a similar trend was noticed for patients with synchronous BM (25.7 months for EGFR MT vs. 6.8 months for EGFR WT, p < 0.001). However, in patients with metachronous BM development, the difference in BM-OS between patients with EGFR MT (14.6 months) and EGFR WT (2.5 months) did not reach statistical significance (p = 0.230). Conclusions: Synchronous BM was more common in NSCLC patients with EGFR MT than in those with EGFR WT. However, EGFR mutations were associated with significantly longer median BM-OS, especially when the brain was the first metastatic site.

키워드

참고문헌

  1. Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 2012;30:419-425.
  2. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-2388. https://doi.org/10.1056/NEJMoa0909530
  3. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957. https://doi.org/10.1056/NEJMoa0810699
  4. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-742. https://doi.org/10.1016/S1470-2045(11)70184-X
  5. Shin DY, Na II, Kim CH, Park S, Baek H, Yang SH. EGFR mutation and brain metastasis in pulmonary adenocarcinomas. J Thorac Oncol 2014;9:195-199. https://doi.org/10.1097/JTO.0000000000000069
  6. Stanic K, Zwitter M, Hitij NT, Kern I, Sadikov A, Cufer T. Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival. Radiol Oncol 2014;48:173-183.
  7. Eichler AF, Kahle KT, Wang DL, et al. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol 2010;12:1193-1199. https://doi.org/10.1093/neuonc/noq076
  8. Lee DW, Shin DY, Kim JW, et al. Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: integrating with lung specific GPA score. Lung Cancer 2014;86:363-368. https://doi.org/10.1016/j.lungcan.2014.10.001
  9. Mak KS, Gainor JF, Niemierko A, et al. Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases. Neuro Oncol 2015;17:296-302. https://doi.org/10.1093/neuonc/nou146
  10. Sekine A, Satoh H, Iwasawa T, et al. Prognostic factors for brain metastases from non-small cell lung cancer with EGFR mutation: influence of stable extracranial disease and erlotinib therapy. Med Oncol 2014;31:228. https://doi.org/10.1007/s12032-014-0228-9
  11. Lee HL, Chung TS, Ting LL, et al. EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in nonsmall cell lung cancer patients with brain metastases. Radiat Oncol 2012;7:181. https://doi.org/10.1186/1748-717X-7-181
  12. Hendriks LE, Smit EF, Vosse BA, et al. EGFR mutated non-small cell lung cancer patients: more prone to development of bone and brain metastases? Lung Cancer 2014;84:86-91. https://doi.org/10.1016/j.lungcan.2014.01.006
  13. Luo D, Ye X, Hu Z, et al. EGFR mutation status and its impact on survival of Chinese non-small cell lung cancer patients with brain metastases. Tumour Biol 2014;35:2437-2444. https://doi.org/10.1007/s13277-013-1323-9
  14. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996;17:343-346. https://doi.org/10.1016/0197-2456(96)00075-X
  15. Nie F, Yang J, Wen S, et al. Involvement of epidermal growth factor receptor overexpression in the promotion of breast cancer brain metastasis. Cancer 2012;118:5198-5209. https://doi.org/10.1002/cncr.27553
  16. Benedettini E, Sholl LM, Peyton M, et al. Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am J Pathol 2010;177:415-423. https://doi.org/10.2353/ajpath.2010.090863
  17. Ceresoli GL, Cappuzzo F, Gregorc V, Bartolini S, Crino L, Villa E. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol 2004;15:1042-1047. https://doi.org/10.1093/annonc/mdh276
  18. Porta R, Sanchez-Torres JM, Paz-Ares L, et al. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J 2011;37:624-631. https://doi.org/10.1183/09031936.00195609
  19. Grommes C, Oxnard GR, Kris MG, et al. "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol 2011;13:1364-1369. https://doi.org/10.1093/neuonc/nor121
  20. Jackman DM, Holmes AJ, Lindeman N, et al. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 2006;24:4517-4520. https://doi.org/10.1200/JCO.2006.06.6126
  21. Heon S, Yeap BY, Lindeman NI, et al. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin Cancer Res 2012;18:4406-4414. https://doi.org/10.1158/1078-0432.CCR-12-0357
  22. Noronha V, Joshi A, Gokarn A, et al. The importance of brain metastasis in EGFR mutation positive NSCLC patients. Chemother Res Pract 2014;2014:856156.

피인용 문헌

  1. EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer vol.17, pp.12, 2018, https://doi.org/10.3390/ijms17122132
  2. Patterns of metastatic progression after definitive radiation therapy for early-stage and locally advanced non-small cell lung cancer vol.34, pp.5, 2018, https://doi.org/10.1007/s10585-017-9850-1
  3. Brain metastases in non-small cell lung cancer patients on epidermal growth factor receptor tyrosine kinase inhibitors: symptom and economic burden vol.20, pp.11, 2017, https://doi.org/10.1080/13696998.2017.1361960
  4. Role of Local Ablative Therapy in Patients with Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer vol.12, pp.2, 2018, https://doi.org/10.1016/j.jtho.2016.10.012
  5. Brain metastases in patients with non-small cell lung cancer: the role of mutated- EGFRs with an exon 19 deletion or L858R point mutation in cancer cell dissemination vol.8, pp.32, 2018, https://doi.org/10.18632/oncotarget.18509
  6. IMP3 expression in NSCLC brain metastases demonstrates its role as a prognostic factor in non-neuroendocrine phenotypes vol.35, pp.1, 2018, https://doi.org/10.1007/s12032-017-1062-7
  7. Therapeutic Effect of First-line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Combined with Whole Brain Radiotherapy on Patients with EGFR Mutation-positive Lung Adenocarcinom vol.38, pp.6, 2018, https://doi.org/10.1007/s11596-018-1984-0
  8. A Comprehensive Meta-Analysis of Association between EGFR Mutation Status and Brain Metastases in NSCLC vol.25, pp.2, 2018, https://doi.org/10.1007/s12253-019-00598-0
  9. Platelet indices in non-small cell lung cancer patients with brain metastases vol.24, pp.4, 2018, https://doi.org/10.3233/cbm-192393
  10. Paradoxical relationship between body mass index and bone mineral density in patients with non-small cell lung cancer with brain metastasis vol.14, pp.6, 2018, https://doi.org/10.1371/journal.pone.0218825
  11. MicroRNA-330-3p promotes brain metastasis and epithelial-mesenchymal transition via GRIA3 in non-small cell lung cancer vol.11, pp.17, 2019, https://doi.org/10.18632/aging.102201
  12. The impact of systemic treatment on brain metastasis in patients with non-small-cell lung cancer: A retrospective nationwide population-based cohort study vol.9, pp.1, 2018, https://doi.org/10.1038/s41598-019-55150-6
  13. The role of EGFR mutation as a prognostic factor in survival after diagnosis of brain metastasis in non-small cell lung cancer: a systematic review and meta-analysis vol.19, pp.None, 2018, https://doi.org/10.1186/s12885-019-5331-z
  14. Clinicopathologic and Imaging Features of Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations vol.11, pp.12, 2019, https://doi.org/10.3390/cancers11122033
  15. Effects of single-nucleotide polymorphisms in the mTORC1 pathway on the risk of brain metastasis in patients with non-small cell lung cancer vol.146, pp.1, 2020, https://doi.org/10.1007/s00432-019-03059-y
  16. Establishment of a Prognostic Nomogram for Lung Adenocarcinoma with Brain Metastases vol.141, pp.None, 2018, https://doi.org/10.1016/j.wneu.2020.05.273
  17. EGFR 敏感突变阴性非小细胞肺癌脑转移患者临床特征 vol.24, pp.1, 2021, https://doi.org/10.3779/j.issn.1009-3419.2020.102.48
  18. Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data vol.21, pp.1, 2021, https://doi.org/10.1186/s12885-021-08713-8
  19. Afatinib in the treatment of brain metastases of lung cancer with one rare EGFR mutation: a two-case report vol.33, pp.1, 2018, https://doi.org/10.1097/cad.0000000000001138